Acute Pancreatitis - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights:

• In 2023, the Acute Pancreatitis market size was highest in the US among the 7MM, accounting for approximately USD 510 million which is further expected to increase by 2034 at a CAGR of 6.9%.
• The acute pancreatitis market is driven by the rising incidence of the disease, advancements in diagnostic technologies, and the development of new therapies. Increasing focus on personalized medicine and growing awareness and education about the condition further contribute to market growth.
• According to DelveInsight's estimates, the total diagnosed prevalent cases of Acute Pancreatitis in the 7MM, were ~509 thousand in 2023.
• The current treatment for Acute Pancreatitis includes pancreatic enzymes, pain medication, and others.
• The emerging drug AUXORA is expected to launch in the US by 2025, in EU4 and the UK by 2026, and in Japan by 2027, which has the potential to reduce the disease burden of Acute Pancreatitis in the forecasted years.
• In a clinical trial study, acute pancreatitis patients treated with AUXORA in addition to standard of care, had multiple improved outcomes, including the ability to tolerate solid food earlier and fewer days spent in the hospital, compared to patients treated with standard of care alone.

DelveInsight's "Acute Pancreatitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Acute Pancreatitis, historical and forecasted epidemiology as well as the Acute Pancreatitis market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

The Acute Pancreatitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Acute Pancreatitis market size from 2020 to 2034. The Acute Pancreatitis Market Report also covers current Acute Pancreatitis treatment practices, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Acute Pancreatitis Treatment Market

Acute Pancreatitis Overview

Acute pancreatitis is characterized by inflammation of the exocrine pancreas which occurs as a result of auto digestion of the pancreas by pancreatic enzymes. AP is associated with acinar cell injury and both a local and systemic inflammatory response. The incidence of acute pancreatitis has been increasing worldwide, but the major etiologies remain gallstones and alcohol.

It may range in severity from self-limiting, characterized by mild pancreatic edema, to severe systemic inflammation with pancreatic necrosis, organ failure and death. There are several clinical, laboratory, and radiologic risk factors and scoring systems that are used to predict severity of AP, but none is optimal. The diagnosis of acute pancreatitis requires at least 2 of the following: typical upper abdominal pain, elevated levels of amylase or lipase, and confirmatory findings from cross-sectional imaging analysis.

Acute Pancreatitis Diagnosis

Acute pancreatitis is confirmed by medical history, physical examination, and typically a blood test (amylase or lipase) for the pancreas' digestive enzymes. Blood amylase or lipase levels are typically elevated 3 times the normal level during acute pancreatitis. In some cases, when the blood tests are not elevated, and the diagnosis is still in question, abdominal imaging, such as a computed tomography (CT) scan, might be performed.

In acute pancreatitis, the pancreatic enzymes amylase, lipase, elastase, and trypsin are simultaneously released into the bloodstream. As the clearance of each of these enzymes varies, the blood sampling's timing from the onset of acute pancreatitis affects the test's sensitivity. Lipase has higher diagnostic accuracy than amylase as the serum lipase levels are elevated for a longer period. Caution should be exercised when interpreting amylase results in patients with hypertriglyceridemia as they can have a falsely low amylase result. During an acute pancreatitis attack, the elevation of alanine aminotransferase to >150 IU/L is a predictive factor for the biliary cause of acute pancreatitis.

Acute Pancreatitis Treatment

Acute pancreatitis is a sudden inflammation of the pancreas requiring prompt treatment. Key steps include fluid resuscitation with IV fluids, pain management, and keeping the patient NPO to rest the pancreas. Oral intake is gradually reintroduced as the patient stabilizes. Treatment may involve addressing underlying causes, such as gallstones or alcohol use, and monitoring for complications like necrosis or pseudocysts. Long-term management may include enzyme replacement therapy and lifestyle changes. A multidisciplinary approach is essential for effective care and recovery.

While most cases of acute pancreatitis are mild, the challenge remains in managing the severe cases and the complications associated with acute pancreatitis. As no curative therapy is currently available for acute pancreatitis, early treatment consists of supportive care which includes adequate fluid resuscitation and pain management. Improvement in diagnostic methods, increase in research initiatives and better understanding of disease pathology will lead to development of novel therapeutic approaches.

Acute Pancreatitis Epidemiology

As the Acute Pancreatitis market is derived using a patient-based model, the Acute Pancreatitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Acute Pancreatitis, Gender-specific Incident Cases of Acute Pancreatitis, Etiology-specific Incident Cases of Acute Pancreatitis, and Severity-specific Incident Cases of Acute Pancreatitis, in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• The highest total Incident Cases of Acute Pancreatitis were accounted by the US in 2023 (~288 thousand), which is expected to show a rise in the future.
• Among the European countries, Germany had the highest Incident Cases of Acute Pancreatitis with ~53 thousand cases, followed by the UK, which had diagnosed prevalent population of ~37 thousand in 2023. On the other hand, Italy had the lowest diagnosed prevalent population (~12 thousand cases).
• Japan had ~61 thousand total Incident Cases of Acute Pancreatitis in 2023, accounting for approximately 12% in 7MM.
• Among Etiology-specific cases of Acute Pancreatitis in Japan, 73% cases were of Non-Gallstone type followed by 27% cases were of Gallstone type.
• In 2023, in the US, the gender-specific Incident Cases of Acute Pancreatitis were highest for females (~55%), as compared to males (~45%), which is attributed to factors such as hormonal differences and physiology, lifestyle and occupational factors and others.
• According to DelveInsight estimates, in 2023 based on severity specific cases approximately 40 thousand cases were of Mild severity, followed by ~12 thousand severe cases, and ~8 thousand cases were of Moderate severity in Japan.
• The management of acute pancreatitis has several unmet needs. Improved diagnostic tools are needed for early detection and prediction of severity. Current treatments are mainly supportive, highlighting the need for targeted therapies that address the disease's underlying causes.

Acute Pancreatitis Drug Chapters

The drug chapter segment of the Acute Pancreatitis market report encloses a detailed analysis of Acute Pancreatitis off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Acute Pancreatitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Acute Pancreatitis Emerging Drugs

AUXORA : CalciMedica, Inc.

AUXORA is a potent and selective small-molecule inhibitor of calcium release-activated calcium (CRAC) channels. CRAC channels are found on many cell types, including immune cells and pancreatic acinar cells, where aberrant activation of these channels is thought to play a key role in the pathobiology of acute pancreatitis. AUXORA arose from CalciMedica's internal R&D, is patent- protected, and is being developed for moderately severe and severe acute pancreatitis.

In May 2017, CalciMedica, Inc., received Fast-Track designation from the US Food and Drug Administration for AUXORA, a novel, calcium release-activated calcium (CRAC) channel inhibitor, for the treatment of acute pancreatitis.

In Nov 2016, the European Commission granted the orphan drug designation to EMAS Pharma Limited, United Kingdom, to AUXORA for the treatment of acute pancreatitis.

In June 2024, CalciMedica reported positive topline results from its Phase IIb CARPO trial, evaluating AUXORA in patients with acute pancreatitis. The trial successfully achieved its primary objective, demonstrating a statistically significant dose-response. Notably, there was a 43.6% relative reduction (equivalent to a 2.1-day improvement) in the median time to solid food tolerance in hyper-inflamed patients compared to placebo.

Additionally, the trial showed a statistically significant reduction of up to 61.7% in severe organ failure across all patients treated with AUXORA versus placebo. Furthermore, the results indicated up to a 100% reduction in hospital stays exceeding 21 days.

CalciMedica is now preparing for an End-of-Phase II meeting with the FDA, setting the stage for a pivotal trial. The final data from this study is anticipated in the second half of 2024.

Further detail in the report...

Acute Pancreatitis Market Outlook

The United States accounts for the highest Acute Pancreatitis market size amongst the 7MM, during the forecast period [2024-2034].

The management of acute pancreatitis depends on the severity of disease and the concomitant complications that may arise. The treatment approach is usually based on the extent of severity and the underlying cause of the disease. The primary goal of the treatment is to relieve the pain and reduce the inflammation associated with the Pancreas. Currently, there is no therapy that is approved by the FDA to treat Acute Pancreatitis, therefore the treatment generally focuses on relieving the symptoms of pain, inflammation and any underlying complications that arises due to it.

The treatment of Acute pancreatitis requires hospitalization wherein the therapeutic approach is to provide fluids intravenously in order to provide adequate nutrition, analgesics are given to relieve the pain, antibiotics are recommended only when there are any infections associated with the underlying disease, diabetic medication is also given in the cases of hyperglycemia, certain pancreatic enzymes are also recommended for the treatment. Apart from these certain procedural therapies are also advised in the case of severe disease and when the cause for the disease is gall stones (biliary). The stones are usually passed on with the medications but in the case of severe disease and non-removal of stone by the given medications endoscopy, such as ERCP procedure, Endoscopic sphincterotomy, Cholecystectomy is recommended. Cholecystectomy involves the removal of gall bladder in severe cases of biliary acute pancreatitis but is only performed when the inflammation is reduced.

The treatment cost quoted in majority of the published literature includes the total cost of hospitalization involving the cost of hospital bed, the day to day hospital cost, the cost of diagnostic procedures (ultrasound, computed tomography, Magnetic resonance cholangiopancreatography, Endoscopic retrograde cholangiopancreatography), the cost of surgical procedures (Biliary sphincterotomy, Cholecystectomy, Pancreatic duct stone removal and many others) and the cost of medical therapies. Inpatient costs for acute pancreatitis also varies widely by state in the United States. The reason for this variation was found out to be patient demographics, hospital characteristics and case mix variables.

However, our forecasting model only focuses on the pharmacological therapies involved in the treatment of Acute Pancreatitis such as pancreatic enzymes, pain medication and other treatment options such as diabetes medication, antibiotics, hydration therapy, and parenteral nutrition

In the upcoming treatment landscape, there are many Acute Pancreatitis companies investigating agents for use which includes CalciMedica, Inc. and others. There are many more pharma companies which are conducting clinical trials for therapies for Acute Pancreatitis.

• The Acute Pancreatitis therapeutic market size in the 7MM was approximately USD 722 million in 2023, the market is expected to grow at a Compound annual growth rate (CAGR) of 6% during the forecast period (2024-2034) attributed to the advanced therapies, and others.
• The United States accounted for the highest Acute Pancreatitis market size approximately 71% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Among the European countries, Germany had the highest Acute Pancreatitis market size with nearly USD 53 million in 2023, while Italy had the lowest Acute Pancreatitis market size with nearly USD 12 million in 2023.
• The Acute Pancreatitis market size in Japan was estimated to be nearly USD 54 million in 2023, which accounts for 7% of the total 7MM Acute Pancreatitis market.
• With the expected launch of upcoming Acute Pancreatitis therapies, such as AUXORA the total Acute Pancreatitis market size is expected to show change in the upcoming years.

Acute Pancreatitis Drugs Uptake

This section focuses on the uptake rate of potential Acute Pancreatitis drugs expected to launch in the Acute Pancreatitis market during 2020-2034. For example, AUXORA in the US is expected to be launched by 2025 with a peak share of 12%. AUXORA is anticipated to take 6 years to peak with a medium uptake.

Acute Pancreatitis Pipeline Development Activities

The Acute Pancreatitis market report provides insights into different Acute Pancreatitis clinical trials within Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Acute Pancreatitis market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Acute Pancreatitis emerging therapies.

Acute Pancreatitis KOL Views

To keep up with current Acute Pancreatitis market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Acute Pancreatitis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from Creighton University, US; State University of New York, Health Sciences Center, Brooklyn, New York, US; University of Virginia, Charlottesville, Virginia, US; University of California, San Diego, San Diego, California, US; Swansea University, Medical School, UK; West Wales General Hospital, Carmarthen, UK; Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Japan; Division of Gastroenterology, Tohoku Medical and Pharmaceutical University, Sendai, Japan; and others.

Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Acute Pancreatitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Acute Pancreatitis market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging Acute Pancreatitis therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Acute Pancreatitis Market Access and Reimbursement

The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.

The Acute Pancreatitis market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Acute Pancreatitis Market Report

• The Acute Pancreatitis market report covers a segment of key events, an executive summary, and a descriptive overview of Acute Pancreatitis, explaining its causes, signs and symptoms, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• Additionally, an all-inclusive account of the current and emerging Acute Pancreatitis therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Acute Pancreatitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind the approach is included in the report covering the 7MM drug outreach.
• The Acute Pancreatitis market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM Acute Pancreatitis market.

Acute Pancreatitis Market Report Insights

• Acute Pancreatitis Patient Population
• Acute Pancreatitis Therapeutic Approaches
• Acute Pancreatitis Pipeline Analysis
• Acute Pancreatitis Market Size
• Acute Pancreatitis Market Trends
• Existing and Future Acute Pancreatitis Market Opportunities

Acute Pancreatitis Market Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Acute Pancreatitis Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Acute Pancreatitis Drugs Uptake
• Key Acute Pancreatitis Market Forecast Assumptions

Acute Pancreatitis Market Report Assessment

• Current Acute Pancreatitis Treatment Practices
• Acute Pancreatitis Unmet Needs
• Acute Pancreatitis Pipeline Product Profiles
• Acute Pancreatitis Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Acute Pancreatitis Market Drivers
• Acute Pancreatitis Market Barriers

Key Questions Answered In The Acute Pancreatitis Market Report

Acute Pancreatitis Market Insights

• What was the Acute Pancreatitis market share (%) distribution in 2020 and what it would look like in 2034?
• What would be the Acute Pancreatitis market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Acute Pancreatitis market size during the forecast period (2024-2034)?
• At what CAGR, the Acute Pancreatitis market is expected to grow at the 7MM level during the forecast period (2024-2034)?
• What would be the Acute Pancreatitis market outlook across the 7MM during the forecast period (2024-2034)?
• What would be the Acute Pancreatitis market growth till 2034 and what will be the resultant market size in the year 2034?
• How would the market drivers, barriers, and future opportunities affect the Acute Pancreatitis market dynamics and subsequent analysis of the associated trends?

Acute Pancreatitis Epidemiology Insights

• What are the disease risk, burden, and unmet needs of Acute Pancreatitis?
• What is the historical Acute Pancreatitis patient population in the United States, EU4 (Germany, France, Italy, Spain), the UK, and Japan?
• What would be the forecasted patient population of Acute Pancreatitis at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Pancreatitis?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Acute Pancreatitis during the forecast period (2024-2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2024-2034)?

Current Acute Pancreatitis Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options for the treatment of Acute Pancreatitis along with the approved therapy?
• What are the current treatment guidelines for the treatment of Acute Pancreatitis in the US, Europe, And Japan?
• What are the Acute Pancreatitis-marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many Acute Pancreatitis companies are developing therapies for the treatment of Acute Pancreatitis?
• How many emerging Acute Pancreatitis therapies are in the mid-stage and late stages of development for the treatment of Acute Pancreatitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the Acute Pancreatitis therapies?
• What are the recent therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What are the clinical studies going on for Acute Pancreatitis and their status?
• What are the key designations that have been granted for the emerging therapies for Acute Pancreatitis?
• What are the 7MM historical and forecasted Acute Pancreatitis market?

Reasons to Buy Acute Pancreatitis Market Report

• The Acute Pancreatitis market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute Pancreatitis Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing Acute Pancreatitis market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current Acute Pancreatitis patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming Acute Pancreatitis companies in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and potential of current and emerging Acute Pancreatitis therapies under the conjoint analysis section to provide visibility around leading emerging drugs.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming Acute Pancreatitis companies can strengthen their development and launch strategy.

Frequently Asked Questions:

1. What is the forecast period covered in the report?

The Acute Pancreatitis Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.

2. Who are the key players in the Acute Pancreatitis market?

The Acute Pancreatitis market is quite robust. The major layers are CalciMedica, Inc. and others which are currently developing drugs for the treatment of Acute Pancreatitis.

3. How is the market size estimated in the forecast report?

The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.

4. What is the key driver of the Acute Pancreatitis market?

The increase in diagnosed prevalent cases of Acute Pancreatitis and the launch of emerging therapies are attributed to be the key drivers for increasing the Acute Pancreatitis market.

5. What is the expected impact of emerging therapies or advancements in Acute Pancreatitis treatment on the market?

Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Acute Pancreatitis treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.

6. Does the report provide insights into the competitive landscape of the market?

The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Acute Pancreatitis market.